Literature DB >> 10545916

Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.

J K Taylor1, Q Q Zhang, J R Wyatt, N M Dean.   

Abstract

Resistance to apoptosis, which plays an important role in tumors that are refractory to chemotherapy, is regulated by the ratio of antiapoptotic to proapoptotic proteins. By manipulating levels of these proteins, cells can become sensitized to undergo apoptosis in response to chemotherapeutic agents. Alternative splicing of the bcl-x gene gives rise to two proteins with antagonistic functions: Bcl-xL, a well-characterized antiapoptotic protein, and Bcl-xS, a proapoptotic protein. We show here that altering the ratio of Bcl-xL to Bcl-xS in the cell using an antisense oligonucleotide permitted cells to be sensitized to undergo apoptosis in response to ultraviolet B radiation and chemotherapeutic drug treatment. These results demonstrate the ability of a chemically modified oligonucleotide to alter splice site selection in an endogenous gene and illustrate a powerful tool to regulate cell survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545916     DOI: 10.1038/15079

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  50 in total

1.  Temperature-dependent splicing of beta-globin pre-mRNA.

Authors:  Federica Gemignani; Peter Sazani; Paul Morcos; Ryszard Kole
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

2.  Modulation of RNA splicing as a potential treatment for cancer.

Authors:  John A Bauman; Ryszard Kole
Journal:  Bioeng Bugs       Date:  2011-05-01

Review 3.  Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.

Authors:  Peter Sazani; Ryszard Kole
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

4.  hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing.

Authors:  Rachel Wilson Goehe; Jacqueline C Shultz; Charuta Murudkar; Sanja Usanovic; Nadia F Lamour; Davis H Massey; Lian Zhang; D Ross Camidge; Jerry W Shay; John D Minna; Charles E Chalfant
Journal:  J Clin Invest       Date:  2010-10-25       Impact factor: 14.808

5.  The emerging role of splicing factors in cancer.

Authors:  Ana Rita Grosso; Sandra Martins; Maria Carmo-Fonseca
Journal:  EMBO Rep       Date:  2008-10-10       Impact factor: 8.807

6.  Aberrant splicing of the E-cadherin transcript is a novel mechanism of gene silencing in chronic lymphocytic leukemia cells.

Authors:  Sanjai Sharma; Alan Lichtenstein
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

Review 7.  Alternative splicing as a biomarker and potential target for drug discovery.

Authors:  Kai-qin Le; Bellur S Prabhakar; Wan-jin Hong; Liang-cheng Li
Journal:  Acta Pharmacol Sin       Date:  2015-06-15       Impact factor: 6.150

8.  Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5' splice site selection.

Authors:  Anyu Zhou; Alexander C Ou; Aeri Cho; Edward J Benz; Shu-Ching Huang
Journal:  Mol Cell Biol       Date:  2008-07-28       Impact factor: 4.272

9.  Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.

Authors:  Takehiko Shiraishi; Jonhard Eysturskarth; Peter E Nielsen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

Review 10.  Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies.

Authors:  Jianhua Zhou; Qingming Yu; Tie Zou
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.